8-K: Lyell Immunopharma Reports Q3 2025 Results, Pipeline Advances

Lyell Immunopharma announced its third quarter 2025 financial results and significant progress in its CAR T-cell therapy pipeline, including new RMAT designations and clinical trial initiations.

Summary

• Net loss for the third quarter ended September 30, 2025, was $38.8 million, an improvement from a net loss of $44.6 million for the same period in 2024.
• Non-GAAP net loss decreased to $29.1 million for Q3 2025, compared to $37.1 million for Q3 2024.
• Research and development (R&D) expenses decreased by $11.3 million to $28.2 million in Q3 2025, primarily due to reduced research activities, collaborations, outside services, and personnel-related expenses.
• General and administrative (G&A) expenses decreased by $1.1 million to $10.7 million in Q3 2025, mainly due to lower stock-based compensation and legal expenses.
• Cash, cash equivalents, and marketable securities were approximately $320 million as of September 30, 2025, down from $384 million as of December 31, 2024.
• Current cash is expected to support advancing the pipeline into 2027 through key clinical milestones.
• Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate for refractory metastatic colorectal cancer (mCRC).
• LYL273 demonstrated a 67% overall response rate (ORR) and an 83% disease control rate (DCR) at the highest dose level in a U.S. Phase 1 clinical trial for mCRC.
• Ronde-cel (LYL314) received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line (2L) setting, complementing its existing RMAT for the thirdor later-line (3L+) setting.
• Announced the initiation of PiNACLE H2H, a Phase 3 head-to-head CAR T-cell therapy clinical trial for aggressive LBCL in the 2L setting, with enrollment expected by early 2026.
• Two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of ronde-cel have been accepted for oral presentation at the ASH 67th Annual Meeting and Exposition in December 2025.

Sentiment

Score: 7

Explanation: The company reported improved financial metrics with reduced net loss and operating expenses, alongside significant clinical and regulatory advancements for its lead product candidates, ronde-cel and LYL273. The extension of the cash runway into 2027 and promising early clinical data for LYL273 are strong positives. However, the decrease in cash balance and a patient death in the LYL273 trial introduce some caution regarding clinical risk and cash burn.

Positives

• Net loss decreased by $5.7 million year-over-year, indicating improved financial efficiency.
• Non-GAAP net loss decreased by $8.0 million year-over-year, reflecting better operational performance.
• R&D expenses decreased by $11.3 million, and G&A expenses decreased by $1.1 million, demonstrating effective cost management.
• Cash, cash equivalents, and marketable securities of $320 million are projected to fund operations into 2027, providing a solid financial runway.
• Acquired exclusive global rights to LYL273, a promising CAR T-cell candidate for refractory mCRC, showing a 67% ORR and 83% DCR at the highest dose level in Phase 1.
• Ronde-cel received a second RMAT designation from the FDA for 2L LBCL, which may expedite its development and regulatory review.
• Initiation of the PiNACLE H2H Phase 3 head-to-head trial for ronde-cel in 2L LBCL signifies advancement into pivotal studies.
• Acceptance of two abstracts for oral presentation at the ASH 67th Annual Meeting highlights significant clinical and translational data for ronde-cel.
• LYL273 was granted Fast Track designation for the treatment of mCRC by the FDA.

Negatives

• Cash, cash equivalents, and marketable securities decreased by $64 million from December 31, 2024, to September 30, 2025.
• A $4.0 million loss was incurred related to a put/call asset from a July 2025 securities purchase agreement.
• Interest income decreased due to lower interest rates in 2025 and reduced cash balances.
• One patient in the LYL273 Phase 1 trial experienced a dose-limiting toxicity at Dose Level 2, including Grade 3 diarrhea, Grade 4 enterocolitis, and death from fungal sepsis 48 days post-infusion.

Risks

• Limited experience in enrolling and conducting clinical trials, and lack of experience in completing clinical trials.
• Nonclinical profiles of product candidates or technology may not translate effectively into clinical trials.
• Potential for clinical trial results to differ from nonclinical, early clinical, preliminary, or expected outcomes.
• Significant adverse events, toxicities, or other undesirable side effects associated with product candidates, as evidenced by a patient death in the LYL273 trial.
• Ability to submit planned Investigational New Drug (IND) applications or initiate/progress clinical trials on anticipated timelines, if at all.
• RMAT and Fast Track designations may not necessarily lead to faster development, regulatory review, or approval, and do not guarantee ultimate FDA approval.
• Significant uncertainty regarding product candidates ever receiving any regulatory approvals.
• Challenges in obtaining, maintaining, or protecting intellectual property rights related to product candidates.
• Complexity of manufacturing cellular therapies and the ability to manufacture and supply product candidates for clinical trials.
• Potential reduction of cash resources and fluctuations in operating results due to milestone, royalty, and success payment obligations.
• Sufficiency of capital resources and the potential need for additional capital to achieve goals.
• Effects of macroeconomic conditions, including disruptions due to tariffs or other policies, and geopolitical instability.
• Potential changes to U.S. drug pricing, including most-favored nations pricing limitations.

Future Outlook

Lyell Immunopharma expects to advance its pipeline into 2027 through key clinical milestones, including the initiation of the PiNACLE H2H Phase 3 trial by early 2026, a data update for LYL273 in the first half of 2026, and a Biologics License Application submission for ronde-cel in 3L+ LBCL in 2027. The company also plans to submit its first IND for a fully-armed CAR T-cell product candidate for solid tumors in 2026.

Management Comments

• "We are well positioned with two next-generation CAR T-cell product candidates, each with promising clinical data."
• "We look forward to effectively executing on both clinical programs taking full advantage of our expertise in CAR T-cell clinical development and our wholly-owned manufacturing facility capable of commercial launch."
• "We will be presenting new ronde-cel clinical and translational data at the upcoming ASH meeting and exposition and are focused on rapidly advancing the pivotal development of ronde-cel through our two pivotal programs: PiNACLE H2H, which is expected to begin enrolling patients receiving treatment in the 2L setting by early 2026, and PiNACLE, our ongoing single-arm pivotal trial for patients receiving treatment in the 3L+ setting."

Industry Context

Lyell Immunopharma operates in the highly competitive and rapidly evolving CAR T-cell therapy sector, focusing on both hematologic malignancies and solid tumors. The company's strategy to develop next-generation CAR T-cell therapies designed to overcome T-cell exhaustion and immune suppression aligns with broader industry efforts to improve the durability and efficacy of cell therapies, particularly in challenging tumor microenvironments. The acquisition of LYL273 for metastatic colorectal cancer and the multiple RMAT designations for ronde-cel in large B-cell lymphoma position Lyell to potentially address significant unmet medical needs in these difficult-to-treat cancer types, where existing therapeutic options often have limited success.

Comparison to Industry Standards

• Ronde-cel is a dual-targeting CD19/CD20 CAR T-cell product candidate, designed to increase complete response rates and prolong the duration of response compared to currently approved CD19-targeted CAR T-cell therapies, such as lisocabtagene maraleucel or axicabtagene ciloleucel, which are being used as comparators in the PiNACLE H2H trial.
• LYL273's 67% overall response rate and 83% disease control rate in refractory metastatic colorectal cancer at the highest dose level are notable, given that mCRC is a solid tumor notoriously difficult to treat with cell therapies, and these rates suggest promising activity in an area with high unmet need.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact from reduced net loss, extended cash runway, and significant pipeline advancements (RMATs, Phase 3 initiation, promising LYL273 data). Potential negative from cash burn and a patient death in the LYL273 trial.
• Patients (LBCL): Positive impact from accelerated development of ronde-cel due to RMAT designations and the initiation of a head-to-head Phase 3 trial, offering potential new treatment options.
• Patients (mCRC): Positive impact from promising early data for LYL273, offering hope for a difficult-to-treat cancer, but also a cautionary note due to a dose-limiting toxicity and patient death.
• Employees: Potential for stability and growth given pipeline progress and extended cash runway, though headcount reduction was noted as a reason for decreased personnel expenses.
• Regulatory Authorities (FDA): Increased engagement due to RMAT and Fast Track designations, indicating close collaboration on development pathways.

Next Steps

• Present new ronde-cel clinical and translational data at the ASH 67th Annual Meeting and Exposition in December 2025.
• Initiate enrollment for the PiNACLE H2H Phase 3 trial for LBCL in the 2L setting by early 2026.
• Continue enrolling patients in the Phase 1/2 trial for ronde-cel in the 2L setting until PiNACLE H2H enrollment begins.
• Provide the next data update from the LYL273 Phase 1 clinical trial in the first half of 2026.
• Submit the first IND for a fully-armed CAR T-cell product candidate with an undisclosed target for solid tumors in 2026.
• Submit a Biologics License Application to the FDA in 2027 for ronde-cel for patients with R/R LBCL in the 3L+ setting.
• Continue to enroll patients in the U.S. Phase 1 clinical trial for LYL273 to determine the recommended Phase 2 dose.

Key Dates

Recommendation

Lyell Immunopharma demonstrates strong progress in its clinical pipeline with multiple RMAT designations and the initiation of a pivotal Phase 3 trial for ronde-cel, alongside promising early data for LYL273 in a challenging solid tumor. Financial performance shows improved net loss and expense control, extending the cash runway into 2027. However, the decrease in cash balance and the reported patient death in the LYL273 trial introduce significant clinical risk. While the advancements are positive, the inherent risks of late-stage clinical development in oncology, particularly with cell therapies, warrant a 'hold' position until further clinical data, especially from the pivotal trials, can de-risk the investment profile. The recent capital raise activity also suggests ongoing financing needs.

Keywords

CAR T-cell therapy, lymphoma, colorectal cancer, LBCL, mCRC, LYL273, ronde-cel, LYL314, immunotherapy, clinical trial, FDA RMAT, Phase 3, oncology, biotechnology, Lyell Immunopharma